LU81753A1 - Procede de preparation d'amoxicilline sodique et de compositions d'amoxicilline sodique en doses a injecter et compositions ainsi obtenues - Google Patents

Procede de preparation d'amoxicilline sodique et de compositions d'amoxicilline sodique en doses a injecter et compositions ainsi obtenues Download PDF

Info

Publication number: LU81753A1
Authority: LU; Luxembourg
Prior art keywords: amoxicillin; sodium; solution; sodium hydroxide; compositions
Prior art date: 1978-10-03

Application number

LU81753A

Other languages

English (en)

French (fr)

Inventor

J Groenendaal

G Sijbrands

Jonge H De

Deetman A Bagerman

Original Assignee

Gist Brocades Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-10-03

Filing date

1979-10-03

Publication date

1980-01-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26645454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU81753(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1978-10-03 Priority claimed from NL7809986A external-priority patent/NL7809986A/nl

1979-01-03 Priority claimed from NL7900021A external-priority patent/NL7900021A/nl

1979-10-03 Application filed by Gist Brocades Nv filed Critical Gist Brocades Nv

1980-01-24 Publication of LU81753A1 publication Critical patent/LU81753A1/fr

Links

239000000203 mixture Substances 0.000 title claims description 39
BYHDFCISJXIVBV-YWUHCJSESA-M amoxicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=C(O)C=C1 BYHDFCISJXIVBV-YWUHCJSESA-M 0.000 title claims description 29
238000000034 method Methods 0.000 title claims description 25
238000002360 preparation method Methods 0.000 title claims description 25
238000002347 injection Methods 0.000 title claims description 18
239000007924 injection Substances 0.000 title claims description 18
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 99
239000000243 solution Substances 0.000 claims description 83
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 46
238000004108 freeze drying Methods 0.000 claims description 37
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
229960003022 amoxicillin Drugs 0.000 claims description 30
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 30
239000007864 aqueous solution Substances 0.000 claims description 28
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 22
229960002793 amoxicillin sodium Drugs 0.000 claims description 16
ILVPFTMKCHREDJ-UHFFFAOYSA-N methyl 5-amino-2-fluorobenzoate Chemical group COC(=O)C1=CC(N)=CC=C1F ILVPFTMKCHREDJ-UHFFFAOYSA-N 0.000 claims description 15
238000007710 freezing Methods 0.000 claims description 13
230000008014 freezing Effects 0.000 claims description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
229960004920 amoxicillin trihydrate Drugs 0.000 claims description 11
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
229910052708 sodium Inorganic materials 0.000 claims description 9
239000011734 sodium Substances 0.000 claims description 9
238000001914 filtration Methods 0.000 claims description 8
239000000725 suspension Substances 0.000 claims description 8
239000011780 sodium chloride Substances 0.000 claims description 6
JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 2
206010020751 Hypersensitivity Diseases 0.000 claims description 2
239000013043 chemical agent Substances 0.000 claims 1
238000007796 conventional method Methods 0.000 claims 1
238000001035 drying Methods 0.000 description 51
239000000047 product Substances 0.000 description 28
238000000354 decomposition reaction Methods 0.000 description 15
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
238000010438 heat treatment Methods 0.000 description 11
238000001816 cooling Methods 0.000 description 9
239000011148 porous material Substances 0.000 description 8
238000004040 coloring Methods 0.000 description 7
238000003756 stirring Methods 0.000 description 7
238000004458 analytical method Methods 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
239000007788 liquid Substances 0.000 description 5
239000000523 sample Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000002270 dispersing agent Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
229910052782 aluminium Inorganic materials 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
238000003556 assay Methods 0.000 description 3
239000002585 base Substances 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000002329 infrared spectrum Methods 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
239000010935 stainless steel Substances 0.000 description 3
229910001220 stainless steel Inorganic materials 0.000 description 3
239000000126 substance Substances 0.000 description 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000003513 alkali Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 2
229960000603 cefalotin Drugs 0.000 description 2
238000004891 communication Methods 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
239000010419 fine particle Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
229910052753 mercury Inorganic materials 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
230000002906 microbiologic effect Effects 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000002985 plastic film Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
238000011160 research Methods 0.000 description 2
238000007086 side reaction Methods 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
UDJZTGMLYITLIQ-UHFFFAOYSA-N 1-ethenylpyrrolidine Chemical compound C=CN1CCCC1 UDJZTGMLYITLIQ-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
239000004381 Choline salt Substances 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
-1 alkali metal salts Chemical class 0.000 description 1
KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
229960001931 ampicillin sodium Drugs 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229960001139 cefazolin Drugs 0.000 description 1
MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
235000019417 choline salt Nutrition 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000002788 crimping Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000036512 infertility Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000011017 operating method Methods 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920006255 plastic film Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
238000010926 purge Methods 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
238000003303 reheating Methods 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000004448 titration Methods 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1
238000012795 verification Methods 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

LU81753A 1978-10-03 1979-10-03 Procede de preparation d'amoxicilline sodique et de compositions d'amoxicilline sodique en doses a injecter et compositions ainsi obtenues LU81753A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
NL7809986A NL7809986A (nl)	1978-10-03	1978-10-03	Werkwijze voor het bereiden van natrium amoxicilline geschikt voor injectiepreparaten, alsmede deze verbin- ding bevattende gedoseerde injectiepreparaten en de bereiding ervan.
NL7809986		1978-10-03
NL7900021A NL7900021A (nl)	1979-01-03	1979-01-03	Werkwijze voor het bereiden van natriumamoxicilline geschikt voor injectiepreparaten, alsmede deze verbin- ding bevattende gedoseerde injectiepreparaten en de be- reiding ervan.
NL7900021		1979-01-03

Publications (1)

Publication Number	Publication Date
LU81753A1 true LU81753A1 (fr)	1980-01-24

Family

ID=26645454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU81753A LU81753A1 (fr)	1978-10-03	1979-10-03	Procede de preparation d'amoxicilline sodique et de compositions d'amoxicilline sodique en doses a injecter et compositions ainsi obtenues

Country Status (12)

Country	Link
US (1)	US4607029A (da)
EP (1)	EP0009845B2 (da)
DE (1)	DE2963947D1 (da)
DK (1)	DK157660C (da)
ES (1)	ES484698A1 (da)
FI (1)	FI68518C (da)
FR (1)	FR2437835A1 (da)
GR (1)	GR71663B (da)
IE (1)	IE48953B1 (da)
LU (1)	LU81753A1 (da)
NO (1)	NO155009C (da)
PT (1)	PT70225A (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL8002636A (nl) *	1980-05-08	1981-12-01	Gist Brocades Nv	Solvaat van amoxicilline, werkwijze ter bereiding hiervan en werkwijze ter bereiding van injectiepreparaten uit dit solvaat.
CA1209477A (en) *	1981-03-26	1986-08-12	Bruce E. Haeger	Composition of matter comprising a lyophilized preparation of a penicillin derivative
ES8502863A1 (es) *	1982-09-10	1985-02-01	Glaxo Group Ltd	Un procedimiento para la produccion de un recipiente hermeticamente cerrado que contiene al menos un antibiotico de beta-lactama.
GB8919172D0 (en) *	1989-08-23	1989-10-04	Univ Nottingham	Useful composition
EP1838287B1 (en) *	2005-01-07	2012-05-23	Sandoz Ag	Process for preparing granulates comprising amoxicillin
CN104689302B (zh) *	2015-02-05	2017-06-23	通化东宝药业股份有限公司	一种地特胰岛素注射液的制备方法及其制备的地特胰岛素注射液
CN113577317A (zh) *	2021-07-30	2021-11-02	华北制药集团先泰药业有限公司	一种无菌阿莫西林的制备方法
CN116396307A (zh) *	2023-04-04	2023-07-07	内蒙古联邦动保药品有限公司	一种阿莫西林钠的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3969524A (en) *	1974-08-13	1976-07-13	Hoffmann-La Roche Inc.	Stable amoxicillin dosage form
US4024244A (en) *	1974-09-18	1977-05-17	Beecham Group Limited	Amoxicillin derivatives
GB1463563A (en) *	1974-10-10	1977-02-02	Beecham Group Ltd	Pharmaceutical compositions

1979
- 1979-09-25 PT PT70225A patent/PT70225A/pt unknown
- 1979-09-27 DE DE7979200545T patent/DE2963947D1/de not_active Expired
- 1979-09-27 EP EP79200545A patent/EP0009845B2/en not_active Expired
- 1979-10-02 GR GR60166A patent/GR71663B/el unknown
- 1979-10-02 NO NO793164A patent/NO155009C/no unknown
- 1979-10-02 DK DK413279A patent/DK157660C/da not_active IP Right Cessation
- 1979-10-02 FI FI793049A patent/FI68518C/fi not_active IP Right Cessation
- 1979-10-02 IE IE1875/79A patent/IE48953B1/en not_active IP Right Cessation
- 1979-10-03 FR FR7924654A patent/FR2437835A1/fr active Granted
- 1979-10-03 LU LU81753A patent/LU81753A1/fr unknown
- 1979-10-03 ES ES484698A patent/ES484698A1/es not_active Expired
1985
- 1985-04-23 US US06/726,027 patent/US4607029A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO155009C (no)	1987-01-28
IE48953B1 (en)	1985-06-26
US4607029A (en)	1986-08-19
DK157660B (da)	1990-02-05
EP0009845B1 (en)	1982-10-27
DK413279A (da)	1980-04-04
DK157660C (da)	1990-07-09
NO155009B (no)	1986-10-20
EP0009845B2 (en)	1987-11-11
FR2437835A1 (fr)	1980-04-30
EP0009845A1 (en)	1980-04-16
NO793164L (no)	1980-04-09
ES484698A1 (es)	1980-06-16
FR2437835B1 (da)	1983-03-18
FI68518B (fi)	1985-06-28
IE791875L (en)	1980-04-03
FI793049A7 (fi)	1980-04-04
FI68518C (fi)	1985-10-10
PT70225A (en)	1979-10-01
GR71663B (da)	1983-06-20
DE2963947D1 (en)	1982-12-02

Publication	Publication Date	Title
CA1220718A (fr)	1987-04-21	Composition pharmaceutique a base d'acide valproique et son procede de fabrication
LU84935A1 (fr)	1983-11-23	Nouvelle forme d'ester de cefuroxime,procede pour sa preparation et composition pharmaceutique le contenant
LU83661A1 (fr)	1983-06-08	Derive d'aminoalcoyl furanne,procede pour sa preparation et composition pharmaceutique comprenant ce derive
JPH11147844A (ja)	1999-06-02	残留有機溶媒の除去方法、医薬品製造におけるその使用および調製された物質
LU81753A1 (fr)	1980-01-24	Procede de preparation d'amoxicilline sodique et de compositions d'amoxicilline sodique en doses a injecter et compositions ainsi obtenues
JP2006096761A (ja)	2006-04-13	ホスホリパーゼ阻害剤の［［３−（２−アミノ−１，２−ジオキソエチル）−２−エチル−１−フェニルメチル）−１ｈ−インドール−４−イル］オキシ］酢酸ナトリウムを含む薬学的組成物
LU87102A1 (fr)	1988-08-23	Combinaison iyophilisee ou precipitee de zwitterbn de cephalosporine et de sel
FR2482458A1 (fr)	1981-11-20	Compositions antitumorales a base de methanesulfon-m-anisidine
BE879174A (fr)	1980-04-03	Procede de preparation d'amoxicilline sodique et de compositions d'amoxicilline sodique en doses a injecter et compositions ainsi obtenues
US4002748A (en)	1977-01-11	Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration
EP3148961B1 (fr)	2018-08-22	Procédé de préparation d'un sel d'acide acétylsalicylique et d'un acide aminé basique
CN103462909B (zh)	2015-03-11	一种注射用尼扎替丁制剂
CN103304424B (zh)	2014-08-06	一种二氯醋酸二异丙胺化合物及其复方药物组合物注射剂
FR2470765A1 (fr)	1981-06-12	Nouveaux sels d'addition d'acides du 4'-(9-acridinyl-amino)methanesulf-m-anisidide, leur procede de production et composition pharmaceutique les contenant
US20220402923A1 (en)	2022-12-22	Method for obtaining amorphous remimazolam besylate
TW202220663A (zh)	2022-06-01	含有具有鄰苯二酚基之頭孢菌素類的凍結乾燥製劑及其製造方法
FR2662360A1 (fr)	1991-11-29	Composes d'inclusion de nimesulide avec la cyclodextrine, procedes pour la preparation de ces composes et compositions pharmaceutiques a activite analgesique et anti-inflammatoire les contenant.
WO2016026172A1 (zh)	2016-02-25	无定形盐酸伊伐布雷定及其制备方法与应用
EP0116182B1 (fr)	1986-09-03	Procédé de préparation d'acide p-butoxyphénylacéthydroxamique à l'état finement divisé
FI68055B (fi)	1985-03-29	Foerfarande foer framstaellning av ett snabbloesligt pulver avristallint cefalotinnatrium
US20040007689A1 (en)	2004-01-15	Process for controlling the hydrate mix of a compound
EP1534721B1 (en)	2006-07-26	Process for controlling the hydrate mix of the disodium salt of fosfluconazole
LU83081A1 (fr)	1981-09-10	Compositions antitumeurs
BE887220A (fr)	1981-07-23	Compositions antitumeurs
FI67855B (fi)	1985-02-28	Foerfarande foer framstaellning av ett vaesentligen kristallint laettloesligt cefazolinnatrium